<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00056056</url>
  </required_header>
  <id_info>
    <org_study_id>EORTC-21011</org_study_id>
    <secondary_id>2004-003701-24</secondary_id>
    <nct_id>NCT00056056</nct_id>
  </id_info>
  <brief_title>Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides</brief_title>
  <official_title>A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European Organisation for Research and Treatment of Cancer - EORTC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Ultraviolet light therapy uses light and drugs that make cancer cells more
      sensitive to light to kill tumor cells. It is not yet known whether ultraviolet light therapy
      is more effective with or without bexarotene in treating mycosis fungoides.

      PURPOSE: Randomized phase III trial to compare the effectiveness of ultraviolet light therapy
      using methoxsalen with or without bexarotene in treating patients who have mycosis fungoides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine if ultraviolet A light therapy with methoxsalen (PUVA) with or without
           bexarotene yields a significantly higher overall response rate in patients with mycosis
           fungoides.

        -  Compare the overall response rate (CCR and partial response) in patients treated with
           these regimens.

        -  Compare the duration of CCR and time to relapse of patients treated with these regimens.

        -  Compare the number of PUVA sessions necessary to achieve a CCR in these patients.

        -  Determine the percentage of dropouts by patients treated with these regimens.

        -  Determine the safety of these regimens in these patients.

      OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
      according to participating center, age (60 and under vs over 60), and stage of disease (IB vs
      IIA). Patients are randomized to 1 of 2 treatment arms.

        -  Arm I: Patients receive PUVA comprising oral methoxsalen given 2 hours before whole body
           ultraviolet A therapy. PUVA is given 3 times per week.

        -  Arm II: Patients receive oral bexarotene once daily and PUVA as in arm I. In both arms,
           treatment repeats for up to 16 weeks in the absence of complete clinical response,
           disease progression, or unacceptable toxicity.

      Patients are followed every 8 weeks until the first documented progression or relapse.

      PROJECTED ACCRUAL: A total of 145 patients will be accrued for this study within 25 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor accrual
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (complete clinical response [CCR) and partial response [PR])</measure>
    <time_frame>35 months after first patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative dose of UVA required to achieve CCR</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of PUVA sessions necessary to achieve a CCR</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CCR as measured by Logrank every 4 weeks during treatment and then every 8 weeks until progression</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to relapse</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by CTC v2.0 every 4 weeks during treatment, then every 8 weeks</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of dropouts as measured by the percentage of cases not completing treatment due to toxicity at the completion of treatment</measure>
    <time_frame>35 months after first patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PUVA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bexarotene</intervention_name>
    <description>The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first</description>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methoxypsoralen</intervention_name>
    <description>The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.</description>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
    <arm_group_label>PUVA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UV light therapy</intervention_name>
    <description>Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.</description>
    <arm_group_label>Bexarotene and PUVA</arm_group_label>
    <arm_group_label>PUVA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed mycosis fungoides

               -  Stage IB or IIA

               -  Confirmed by current or prior diagnostic lesion biopsy

        PATIENT CHARACTERISTICS:

        Age

          -  Over 18

        Performance status

          -  Karnofsky 60-100%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 2,000/mm^3

          -  Hemoglobin at least 9 g/dL

        Hepatic

          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)

          -  AST and ALT no greater than 2.5 times ULN

        Renal

          -  Creatinine no greater than 2 times ULN

          -  Calcium no greater than 11.5 mg/dL

        Cardiovascular

          -  No New York Heart Association grade III or IV cardiac insufficiency

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for at least 3 months
             after study participation* NOTE: *Women using hormonal contraception must also use a
             non-hormonal treatment

          -  Fasting triglycerides normal (prior antilipemic agents allowed to reach normalization)

          -  Willing and able to avoid prolonged exposure to the sun

               -  Willing to limit sun exposure on day of PUVA therapy

          -  No prior intolerance of or unresponsiveness to PUVA therapy

          -  No other prior or concurrent malignant tumor except adequately treated carcinoma in
             situ of the cervix or basal cell or squamous cell skin cancer

          -  No prior pancreatitis

          -  No other concurrent serious illness or infection that would preclude study
             participation

          -  No concurrent excessive alcohol consumption

          -  No photosensitivity due to intrinsic (e.g., lupus) or extrinsic (e.g., photosensitive
             drugs) factors

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

          -  No known contraindications to study drug

          -  No known hypersensitivity to retinoids or hypervitaminosis A

          -  No uncontrolled diabetes mellitus

          -  No uncontrolled thyroid disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  At least 3 months since prior interferon therapy

        Chemotherapy

          -  No prior systemic combination chemotherapy

          -  No prior participation in another study of bexarotene

          -  At least 3 months since prior topical chemotherapy

        Endocrine therapy

          -  At least 1 month since prior topical corticosteroids

        Radiotherapy

          -  At least 6 months since prior total skin electron beam therapy

          -  At least 1 month since prior superficial radiotherapy

        Surgery

          -  Not specified

        Other

          -  At least 30 days since prior participation in another investigational drug study

          -  At least 3 months since prior photopheresis

          -  At least 1 month since prior UVB/PUVA phototherapy

          -  At least 1 month since prior retinoid class drugs

          -  At least 1 month since prior beta-carotene compounds

          -  At least 1 month since other prior topical medications (e.g., tar baths)

          -  No prior participation in this study

          -  No other concurrent anticancer therapy

          -  No other concurrent investigational drug therapy

          -  No concurrent drugs associated with pancreatic toxicity or known to increase
             triglyceride concentrations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sean J. Whittaker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>St. Thomas' Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karl-Franzens-University Graz</name>
      <address>
        <city>Graz</city>
        <zip>A-8010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allgemeines Krankenhaus - Universitatskliniken</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ghent University</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.Z. Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR Hotel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Stadt Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Minden</name>
      <address>
        <city>Minden</city>
        <zip>D-32423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Insular de Gran Canaria</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest German Cancer Center at Eberhard-Karls-University</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>County Hospital</name>
      <address>
        <city>Kaposvar</city>
        <zip>H-7400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center - Beilinson Campus</name>
      <address>
        <city>Petah-Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Dermopatico Dell' Immacolata</name>
      <address>
        <city>Rome</city>
        <zip>00167</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Torino</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2300 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Cruz i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Senora de la Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <zip>38003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh at Little France</name>
      <address>
        <city>Edinburgh</city>
        <state>Scotland</state>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Mycosis Fungoides</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
    <mesh_term>Methoxsalen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

